11.14
price down icon1.11%   -0.125
 
loading
Schlusskurs vom Vortag:
$11.27
Offen:
$11.22
24-Stunden-Volumen:
4.41M
Relative Volume:
0.68
Marktkapitalisierung:
$7.73B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
1.9726
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
-3.42%
1M Leistung:
+1.41%
6M Leistung:
-5.79%
1J Leistung:
+2.91%
1-Tages-Spanne:
Value
$11.05
$11.32
1-Wochen-Bereich:
Value
$11.05
$11.66
52-Wochen-Spanne:
Value
$8.73
$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name
Firmenname
Roivant Sciences Ltd
Name
Telefon
441-295-5950
Name
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Name
Mitarbeiter
750
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
ROIV's Discussions on Twitter

Vergleichen Sie ROIV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ROIV
Roivant Sciences Ltd
11.14 7.73B 125.68M 4.81B -781.21M 5.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
546.19 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.73 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
553.83 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.85 28.51B 3.81B -644.79M -669.77M -6.24

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-15 Eingeleitet Wolfe Research Outperform
2024-01-05 Eingeleitet Piper Sandler Overweight
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-17 Eingeleitet Guggenheim Buy
2023-06-08 Eingeleitet BofA Securities Neutral
2022-10-27 Eingeleitet JP Morgan Overweight
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-04-29 Eingeleitet Cantor Fitzgerald Overweight
2021-12-15 Eingeleitet Goldman Buy
2021-11-08 Eingeleitet H.C. Wainwright Buy
2021-10-28 Eingeleitet Citigroup Buy
2021-10-26 Eingeleitet Cowen Outperform
2021-10-26 Eingeleitet Jefferies Buy
2021-10-26 Eingeleitet Truist Buy
Alle ansehen

Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten

pulisher
Jun 18, 2025

HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus

Jun 16, 2025
pulisher
Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia

Jun 10, 2025
pulisher
Jun 09, 2025

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance

Jun 09, 2025
pulisher
Jun 07, 2025

Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks

Jun 07, 2025
pulisher
Jun 04, 2025

(ROIV) Trading Advice - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 31, 2025

Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN

May 31, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World

May 31, 2025
pulisher
May 31, 2025

Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN

May 31, 2025
pulisher
May 30, 2025

Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN

May 30, 2025
pulisher
May 30, 2025

Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

May 30, 2025
pulisher
May 30, 2025

While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey

May 30, 2025
pulisher
May 30, 2025

Roivant Sciences Ltd (ROIV) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada

May 30, 2025
pulisher
May 30, 2025

Roivant Sciences Reports Progress and Financial Results - TipRanks

May 30, 2025
pulisher
May 29, 2025

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates - MSN

May 29, 2025
pulisher
May 29, 2025

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm – Company AnnouncementFT.com - Financial Times

May 29, 2025
pulisher
May 29, 2025

ROIV Crosses Above Key Moving Average Level - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences Q4 2025 Earnings Call Transcript - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences (ROIV) Stock Jumps Nearly 5%: What’s Fueling This Biotech Rally? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Transcript : Roivant Sciences Ltd., Q4 2025 Earnings Call, May 29, 2025 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView

May 29, 2025
pulisher
May 29, 2025

Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences Ltd. Reports Q4 and FY 2025 Financial Results - TradingView

May 29, 2025
pulisher
May 29, 2025

Roivant (ROIV) Reports Decrease in Q4 Revenue but Highlights Strategic Progress | ROIV Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences Fiscal Q4 Net Loss Widens, Revenue Falls - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Earnings Flash (ROIV) Roivant Sciences Reports Q4 Revenue $7.6M, vs. FactSet Est of $54.1M - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

H.C. Wainwright maintains $18 target on Roivant Sciences stock - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

Roivant Sciences (NASDAQ:ROIV) Receives “Buy” Rating from HC Wainwright - Defense World

May 29, 2025
pulisher
May 28, 2025

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock - MSN

May 28, 2025
pulisher
May 28, 2025

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com

May 28, 2025
pulisher
May 28, 2025

Roivant Sciences's Earnings Outlook - Nasdaq

May 28, 2025
pulisher
May 28, 2025

What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings - GuruFocus

May 28, 2025
pulisher
May 28, 2025

H.C. Wainwright maintains $18 target on Roivant Sciences stock By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Roivant Sciences (ROIV) Receives Reiterated Buy Rating from HC W - GuruFocus

May 28, 2025
pulisher
May 25, 2025

Ameriprise Financial Inc. Lowers Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World

May 25, 2025
pulisher
May 24, 2025

(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com

May 24, 2025

Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Venker Eric
President & COO
Jun 20 '25
Sale
11.45
100,000
1,145,000
1,462,223
Ramaswamy Vivek
10% Owner
Jun 20 '25
Sale
11.46
577,007
6,612,500
37,284,108
Ramaswamy Vivek
10% Owner
Jun 18 '25
Sale
11.45
565,266
6,472,296
37,861,115
$21.05
price up icon 1.77%
$35.85
price down icon 0.53%
$21.32
price down icon 0.15%
$99.46
price down icon 1.19%
$108.80
price up icon 2.21%
biotechnology ONC
$246.51
price up icon 1.76%
Kapitalisierung:     |  Volumen (24h):